All stock reports

AARTIDRUGS evidence report

Evidence date: 2026-10-01. Research observations only.

What can I do with this stock?

Evaluated 2026-10-02T01:37:53.224812+00:00. Closed-session evidence: 2026-10-01. This is a timestamped assessment, not a live trading feed.

Strategy evidence, instrument feasibility and portfolio suitability are separate. Portfolio suitability has not been assessed.

Today: intraday

Evidence unavailable

No current intraday signal and observed quote supplied; daily bars cannot establish a live setup.

  • No current intraday signal and observed quote supplied; daily bars cannot establish a live setup.

Next week: five trading sessions

No qualifying opportunity

No candidate with a primary five-session horizon in the coherent source run.

  • No candidate with a primary five-session horizon in the coherent source run.

Long term: one to three years

Research only

A financial screen alone does not establish an investment recommendation.

  • A current, source-backed thesis and valuation review is required.

Investment evidence

Statement coverage
FULL_STATEMENTS
Financial source retrieved
2026-08-25T23:17:17.240021+00:00

Metrics

latest_annual_period
2026-03-31
revenue
25653100000.0
net_income
1949197000.0
operating_cash_flow
2224100000.0
free_cash_flow
490900000.0
total_assets
28152600000.0
total_liabilities
12660400000.0
total_equity
15488600000.0
cash
242800000.0
total_debt
5766400000.0
revenue_growth
0.07468695408101289
earnings_growth
0.1591323739295909
net_margin
0.07598290265114158
roe
0.12584720374985472
debt_to_equity
0.372299626822308
cash_conversion
1.1410339745033469
free_cash_flow_margin
0.01913608881577665
trailing_pe
20.1887
forward_pe
0.0
peg_ratio
Not supplied
price_to_book
2.4526
dividend_yield
0.0

Other positional research

Research only

1 opportunity assessments; compare evidence and conditions below.

Trend Continuation Pullback

Research only. Direction: LONG.

Tests continuation after a controlled retracement within an established trend

  • No active, unexpired validation authority for this exact strategy and horizon.
  • A source-backed entry, invalidation, exit and cost plan is not supplied.
Eligible expression
None selected
Expression comparison
No eligible instrument selected.
Invalidation
Price breach below slow EMA
Entry rule
Not supplied
Entry range (INR)
Not supplied
Exit / review rule
Not supplied
Planned exit
Not supplied
Plan valid until
Not supplied
Promotion reference
Not supplied
Instrument scenarios in INR; quantities are illustrative, not personal sizing
InstrumentEvidence statusContractQuantityCapital / marginTarget P&L after costsStop-level scenario P&LStress lossConditions and limitations
NO_POSITIONAvailableNot suppliedNot suppliedNot supplied0.000.00Not suppliedNo new position; incremental trading P&L is zero.
CASHUnavailableNot suppliedNot suppliedNot suppliedNot suppliedNot suppliedNot suppliedObserved contract, quote and cost evidence not supplied.
FUTURESUnavailableNot suppliedNot suppliedNot suppliedNot suppliedNot suppliedNot suppliedObserved contract, quote and cost evidence not supplied.
OPTIONSUnavailableNot suppliedNot suppliedNot suppliedNot suppliedNot suppliedNot suppliedObserved contract, quote and cost evidence not supplied.
  • No reader capital or loss budget supplied
Decision provenance and limitations
Decision ID
decision-e9a6d93db8bf02b78b00b2ff5b8125b65be2389f43aafa31bb669ac093581879
Policy
stock-decisions-v1
Evidence bundle hash
bf4c279e9e2e19729c353b722ebc1a41dc375cedb0358bdcb60aafb2ef8413c9
  • market-brief: a7de4d64fedac164d48cdfb9b4081a4666d7f797f7d9c58da304b329b3a61d3c
  • validation-registry: b1069587129bfc64a703cdf8322d0294692585b7d67f5472593e4164bbb0c3bc
  • financial-statements: 80e44724925888185416fb4763ae69572014286c4221e0773688949582c29517
  • daily-price: 2f5a3fc782a689ce3721a65bb02ffe298574183330cfcb3ea9073bd016c255ce
  • Conditional research decisions are not orders or personalized position sizes.
  • Scenario payoffs are assumptions, not probabilities or expected returns.
  • A stop price does not guarantee a maximum loss through a gap or illiquidity.

Download the decision evidence as JSON

Evidence briefing

The local language model selected and grouped the following supplied facts.

Overview

The cached financial metric revenue growth is 0.07468695408101289. The cached financial metric roe is 0.12584720374985472. The cached financial metric net margin is 0.07598290265114158. The trailing 20-session price return was 0.83%. The trailing 60-session price return was 7.78%.

Risks

Price source verification: VERIFIED. The closing price was -19.07% below its highest close in the available trailing year. The cached financial metric free cash flow margin is 0.01913608881577665. Historical observations do not establish future returns. No verified current news or catalyst evidence is supplied.

Follow Up

Average cached traded value over twenty sessions was INR 89,864,455. The cached financial metric debt to equity is 0.372299626822308. The trailing 5-session price return was -3.88%. The trailing 250-session price return was -9.97%.

Cached observations and evidence limits